At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 123 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Abatacept 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects Who Switch From Intravenous to Subcutaneous Abatacept Therapy
In Brief
A Phase 3 clinical trial evaluating Abatacept for Arthritis, Rheumatoid. Completed, enrolled 123 participants across 30 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesCanada, Mexico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionDec 2009
Study CompletionJan 2012
TodayJul 2026
First PostedApr 22, 2008
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.2 years ago
Interventions
Abataceptdrug
Subcutaneous injection, 125 mg/mL, once weekly, 48 months